<DOC>
	<DOC>NCT02330276</DOC>
	<brief_summary>Early Phase Pre-Clinical and Initial Clinical Research on (+)- Epicatechin.</brief_summary>
	<brief_title>Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin</brief_title>
	<detailed_description>This project is a double-blinded randomized Phase I study that will include dose-ranging one day PK and pharmacodynamic (PD) studies. Subjects will include healthy individuals and subjects who meet the American Diabetes Association (ADA) criteria for pre-diabetes, including IFG.</detailed_description>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Healthy or prediabetic based on medical history Male or female Must be 21 to 75 years of age (inclusive) Able to give informed consent to the procedures If female, must be either postmenopausal or test negative for pregnancy at screening and on the day of the procedure. Women on estrogen therapy will be included. If of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study Medication use stable for 4 weeks Body Mass Index (BMI) &gt; 27 kg/m2 Definition of prediabetes: impaired fasting glucose (IFG, fasting glucose = 100125 mg/dL) and elevated HbA1c (5.76.4%), each in the absence of other risk factors for diabetes Type 2 diabetes Pregnancy Younger than 21 or older than 75 years of age Clinically significant abnormalities in liver or kidney function (&gt;3x ULN), determined in the last 6 months by a certified clinical laboratory Recent MI or stroke (within 6 months of screening) Blood pressure (BP) &gt;160 mmHg Systolic and &gt;100 mmHg Diastolic Medications thiazolidinediones, any steroids, antidepressants, weight loss drugs Other diseases, besides type 2 diabetes, influencing carbohydrate metabolism</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>